SCHEMBL4325248

SCHEMBL4325248

O=C(O)CCCCC(=O)Nc1c(C(=O)Nc2ccc(Cl)cn2)oc2ccccc12

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 2/20 0.61
▸ LMNA P02545 2/20 0.51
▸ NPC1 O15118 3/20 0.49
▸ L3MBTL1 Q9Y468 2/20 0.49
▸ GLA P06280 1/20 0.49
▸ MAPK1 P28482 1/20 0.49
▸ TSHR P16473 2/20 0.48
▸ RAB9A P51151 5/20 0.47
▸ TP53 P04637 3/20 0.47
▸ KDM4E B2RXH2 3/20 0.47
▸ NFKB1 P19838 1/20 0.47
▸ NFKB2 Q00653 1/20 0.47
▸ RELA Q04206 1/20 0.47
▸ CASP3 P42574 1/20 0.47
▸ KMT2A Q03164 1/20 0.47
▸ SENP7 Q9BQF6 1/20 0.47
▸ SENP6 Q9GZR1 1/20 0.47
▸ POLB P06746 3/20 0.46
▸ HPGD P15428 2/20 0.45
▸ PKM P14618 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4325430 0.98 SMN1; SMN2 (0.61) SMN1; SMN2LMNANPC1L3MBTL1GLA
SCHEMBL13665038 0.91 SMN1; SMN2 (0.63) SMN1; SMN2LMNANPC1L3MBTL1GLA
SCHEMBL4327316 0.90 SMN1; SMN2 (0.61) SMN1; SMN2LMNANPC1L3MBTL1GLA
SCHEMBL13665029 0.89 SMN1; SMN2 (0.60) SMN1; SMN2LMNANPC1L3MBTL1GLA
SCHEMBL4326027 0.88 SMN1; SMN2 (0.61) SMN1; SMN2LMNANPC1L3MBTL1GLA
SCHEMBL13665012 0.87 SMN1; SMN2 (0.60) SMN1; SMN2LMNANPC1L3MBTL1GLA
SCHEMBL13665037 0.86 SMN1; SMN2 (0.57) SMN1; SMN2LMNANPC1L3MBTL1GLA
SCHEMBL13665028 0.86 SMN1; SMN2 (0.55) SMN1; SMN2LMNANPC1L3MBTL1GLA
SCHEMBL13665036 0.86 SMN1; SMN2 (0.54) SMN1; SMN2LMNANPC1L3MBTL1GLA
SCHEMBL4319627 0.85 SMN1; SMN2 (0.60) SMN1; SMN2LMNANPC1L3MBTL1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7605158-B2 Carbamoyl-type benzofuran derivatives MITSUBISHI TANABE PHARMA CORPORATION (JP) 2009-10-20 — — US disclosed
US-7605158-B2 Carbamoyl-type benzofuran derivatives MITSUBISHI TANABE PHARMA CORPORATION (JP) 2009-10-20 — — US disclosed
US-7605158-B2 Carbamoyl-type benzofuran derivatives MITSUBISHI TANABE PHARMA CORPORATION (JP) 2009-10-20 — — US disclosed
US-20060247273-A1 Carbamoyl-type benzofuran derivatives MITSUBISHI TANABE PHARMA CORPORATION (JP) 2006-11-02 — — US disclosed
EP-1666478-A1 CARBAMOYL-TYPE BENZOFURAN DERIVATIVES TANABE SEIYAKU CO., LTD. (JP) 2006-06-07 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060247273-A1 Carbamoyl-type benzofuran derivatives F12, F2, F3 SMN1; SMN2 4587/4885LMNA 3286/4885NPC1 3578/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback